Tonix Pharmaceuticals names CEO Seth Lederman as interim chief medical officer
The board added the interim CMO role to Lederman's existing duties as president, CEO, and chairman, effective August 18, 2026.
SEC filing
Latest
5 stories
Tuesday, August 18
Monday, August 10
Tonix reports Q2 2026 results, TONMYA sales rise 197%, HORIZON trial begins
Tonix Pharmaceuticals said TONMYA net sales grew as it enrolled its first HORIZON trial patient and prepared to expand its sales force and Lyme disease study.
SEC filing
Monday, August 3
Tonix says FDA aligns on Phase 2 design for Lyme antibody TNX-4800
Tonix Pharmaceuticals reported that a Type C meeting with the FDA yielded agreement on the design of an adaptive Phase 2 field study for its monoclonal antibody TNX-4800, with a planned start in early 2027.
SEC filing
Tuesday, July 28
Yale registers Phase 2 trial of Tonix's TNX-1900 for pituitary surgery pain
Tuesday, July 21
Tonix Pharmaceuticals CMO Gregory Sullivan to retire in August 2026
The company disclosed the retirement in an 8-K filing dated July 21, 2026, with an effective date the following month.
SEC filing